Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Moli1901 in Cystic Fibrosis
NCT00671736Phase 2Completed
- Sponsor
- AOP Health
- Start
- Oct 2007
- Primary completion
- Jul 2009
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Lancovutide in cystic fibrosis (CF) (4 arms), sponsored by AOP Health. Primary endpoint: Change in percentage of predicted Forced Expiratory Volume in 1 second. Started Oct 2007; status: completed.
02
Drugs
Lancovutide
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT00671736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00671736.